The PDPN–CLEC2 interaction can enhance tumor growth and metastasis and could cause thromboembolism in cancer patients by promoting platelet-tumor cell aggregation and releasing pro-tumorigenic factors [11,36,54,55,56,57,58,59]. Here, CLEC1B is linked to cancer.